We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Testing for Hypercholesterolemia Improves Diagnosis

By LabMedica International staff writers
Posted on 16 Aug 2018
Print article
Image: Molecular basis of familial hypercholesterolemia with a dominant pattern of inheritance: impaired low-density lipoprotein cholesterol clearance due to variations in LDLR, APOB, PCSK9 (Photo courtesy of Mayo Clinic).
Image: Molecular basis of familial hypercholesterolemia with a dominant pattern of inheritance: impaired low-density lipoprotein cholesterol clearance due to variations in LDLR, APOB, PCSK9 (Photo courtesy of Mayo Clinic).
Familial Hypercholesterolemia (FH) is caused by a genetic defect that hinders the body's ability to remove low-density lipoprotein (LDL) cholesterol from the blood. High LDL levels in the blood are more likely to result in narrowing of the arteries, which puts patients at substantially higher lifetime risk for heart disease and stroke at an early age.

The condition occurs in around 1 out of 220 people and it is estimated that there are 30 million people with FH worldwide. However, FH is significantly underdiagnosed, largely due to the wide spectrum of phenotypes caused by a range of pathogenic variants. It is reported that more than 90% of patients worldwide and more than one million in the USA remain undiagnosed.

An expert panel led by the Geisinger Genomic Medicine Institute (Danville, PA, USA) has recommended that genetic testing should be the standard of care for patients who have a definite or probable diagnosis for FH based on clinical factors and family history. Wider use of genetic testing to identify FH patients is necessary, according to the expert panel, since cardiovascular conditions and other disease phenotypes might show up in a minority of patients, and there might be incomplete information on the prevalence of such conditions among relatives. Moreover, while patients with pathogenic FH variants generally have higher LDL-C levels, studies have shown a wide range of levels among patients.

The scientists recommended that those with very high LDL cholesterol and a positive family history of high cholesterol or early heart attack should be evaluated for pathogenic variants in at least three genes: low density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9), though doctors may assess other genes based on a patient's specific phenotype. More than 2,000 unique genetic variants associated with FH have been identified to date, with around half being classified as pathogenic or likely pathogenic. More than 90% of pathogenic variants are in LDLR, between 5% and 10% are in APOB, and less than 1% are in PCSK9. Genetic testing doesn't always detect a pathogenic variant in one of these genes, and the authors noted that FH should be diagnosed clinically in the event of a negative test result.

Daniel J Rader, MD, a Professor of Molecular Medicine and a senior co-author of the study said, “In this era of precision medicine, genetic testing is an important tool to identify people at high risk for FH and guide the management of their LDL cholesterol to reduce long-term morbidity and mortality from early and aggressive CAD. Physicians should entertain the diagnosis of FH in their patients who have a family history of early heart disease and/or high LDL cholesterol, and consider offering a genetic test in those who may have FH.” The study was published in the August 2018 issue of the Journal of the American College of Cardiology.

Related Links:
Geisinger Genomic Medicine Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.